Organon & Co. (OGN) Announces Discontinuation of the OG-6219 Clinical Development Program

Organon & Co. (NYSE:OGN) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On July 2, Organon & Co. (NYSE:OGN) announced that its Phase 2 ELENA proof-of-concept study did not meet its primary efficacy endpoint. The study evaluated the investigational candidate OG-6219 in endometriosis-related pain, with OG-6219 being an oral 17β-hydroxysteroid dehydrogenase type 1 inhibitor.

Organon & Co. (NYSE:OGN) acquired OG-6219 through its 2021 acquisition of Forendo Pharma. The compound did not exhibit improvement in moderate-to-severe endometriosis-related overall pelvic pain in the study as compared to the placebo, which is why Organon & Co. (NYSE:OGN) plans to discontinue the clinical development program.

Juan Camilo Arjona Ferreira, M.D., Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE: OGN), stated that while the study results were disappointing, the company remains committed to its focus on improving the lives of women with endometriosis.

Organon & Co. (NYSE:OGN) is a global pharmaceutical company that develops and delivers innovative health solutions via a portfolio of prescription therapies within women’s health, established brands, and biosimilars.

While we acknowledge the potential of OGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.